DEF: Penumbra, Inc. Schedules 2026 Annual Meeting and Announces Merger Agreement

Penumbra, Inc. has announced its 2026 Annual Meeting of Stockholders and a definitive merger agreement with Boston Scientific Corporation.

Summary

• Penumbra, Inc. is holding its 2026 Annual Meeting of Stockholders on June 18, 2026, to elect directors, ratify the appointment of PricewaterhouseCoopers LLP as its independent auditor, and approve executive compensation on an advisory basis.
• The company has entered into a definitive merger agreement with Boston Scientific Corporation, valued at approximately $14.5 billion, with a per-share price of $374.
• The transaction is expected to close by the end of 2026, subject to stockholder and regulatory approvals.
• Stockholders will vote on the merger at a separate Special Meeting, not at the Annual Meeting.
• The proxy materials are available online at www.proxyvote.com.
• The company's Board of Directors is transitioning to a declassified board structure over three years, starting with the 2026 Annual Meeting.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive due to the significant merger agreement with Boston Scientific, which offers a substantial premium to shareholders. However, the routine nature of the annual meeting proposals and the disclosure of a director's past SEC settlement temper the overall sentiment.

Positives

• The company has entered into a significant merger agreement with Boston Scientific Corporation at a substantial enterprise value of approximately $14.5 billion.
• The merger offers stockholders a premium of $374 per share, with a choice of cash or Boston Scientific stock.
• The company's Board of Directors is actively transitioning to a declassified structure, enhancing corporate governance.
• All independent directors meet NYSE listing standards and relevant securities laws.
• The Audit Committee has reviewed and discussed the 2025 financial statements with management and PwC, concluding they are prepared in accordance with GAAP.
• The Compensation Committee has reviewed executive compensation and determined that current policies do not encourage undue risk-taking.
• The company's CEO, Adam Elsesser, has voluntarily kept his cash compensation below market rates to reinvest in the business.
• The company's 2025 'Say-on-Pay' vote received approximately 98% approval from voting stockholders.

Negatives

• Harpreet Grewal, a current director, settled SEC litigation in December 2019 regarding alleged violations of securities laws, resulting in a permanent injunction and a $350,000 fine.
• The company's executive compensation, while emphasizing equity, results in total cash compensation for most NEOs being below the 10th percentile of the competitive market, except for Mr. Shiu.
• The company's CEO pay ratio of 11:1, while seemingly low, is based on a median employee compensation of $74,923, which may be considered low for a company of this size and industry.

Risks

• The merger with Boston Scientific Corporation is subject to customary closing conditions, including stockholder and regulatory approvals, which may not be obtained.
• If stockholders fail to ratify the selection of PwC, the Board will reconsider the appointment.
• The company's stock options and RSUs may vest immediately upon a change in control, as defined in the equity plans, which could lead to significant payouts.
• The company's reliance on equity awards for executive compensation, while aligning interests, could be impacted by stock price volatility.
• The company's CEO, Adam Elsesser, has a significant portion of his shares held in a revocable trust, which could have implications for voting control or estate planning.

Future Outlook

The company expects the merger with Boston Scientific Corporation to close by the end of 2026, subject to customary closing conditions, including stockholder and regulatory approvals. The company is also preparing for its 2026 Annual Meeting of Stockholders, which will include the election of directors, ratification of the independent auditor, and an advisory vote on executive compensation.

Management Comments

• Stockholders are cordially invited to attend the Annual Meeting in person.
• Whether or not you expect to attend the Annual Meeting, please complete, date, sign and return the accompanying proxy card, or vote over the telephone or internet as instructed in these materials, as promptly as possible in order to ensure your representation at the Annual Meeting.
• Even if you have voted by proxy, you may still vote in person if you attend the Annual Meeting.
• The Board believes that combining the Chief Executive Officer and Board Chair positions helps ensure that the Board and management act with a common purpose.
• Mr. Elsesser has expressed a preference to the Compensation Committee that his cash compensation be modest so we could invest in other areas of the business.

Industry Context

StockSavvy.ai notes that Penumbra's proposed acquisition by Boston Scientific is a significant event in the medical device industry, reflecting ongoing consolidation and the high valuations placed on innovative companies in the neurovascular and peripheral vascular spaces. This move by Boston Scientific underscores the strategic importance of Penumbra's technology and market position.

Comparison to Industry Standards

• Penumbra's executive compensation philosophy emphasizes long-term equity awards and base salary, a common practice in the technology and medical device sectors to align executive and shareholder interests.
• The company's peer group for compensation analysis includes companies like 10x Genomics, Bio-Techne, and CONMED, which are comparable in the healthcare equipment, supplies, and technology sectors.
• The total cash compensation for most of Penumbra's NEOs is below the 10th percentile of its competitive market, which is a deviation from some industry standards that might offer higher cash incentives.
• The company's CEO pay ratio of 11:1 is relatively low compared to some other large public companies, suggesting a more compressed pay structure at the executive level relative to the median employee.

Corporate Governance

Legal Proceedings

• Harpreet Grewal, a current director, settled litigation instituted by the SEC in December 2019, alleging violations of securities laws. He consented to a Final Judgment permanently enjoining him from future violations and requiring him to pay a fine of $350,000, including a $100,000 civil penalty. He did not admit or deny the allegations.
• There are no other material legal proceedings in which any director, officer, affiliate, or significant stockholder is a party adverse to the Company or has a material interest adverse to the Company.

Related Party Transactions

• Aidan Elsesser, son of Chairman and CEO Adam Elsesser, is a non-executive employee receiving compensation exceeding $120,000 in 2025 and expected for 2026.
• The spouse of Shruthi Narayan, President, is the Founder and CEO of N28 Technologies Inc. (N28). Penumbra has entered into commercial agreements with N28 for IT services, with approximately $0.4 million paid to N28 since January 1, 2025.

Stakeholder Impact

• Shareholders: Will benefit from the proposed merger with Boston Scientific, which offers a $374 per share premium. They will also vote on director elections and executive compensation.
• Employees: The merger may lead to changes in organizational structure and roles post-acquisition. Executive compensation is structured to align long-term interests, with a focus on equity awards.
• Management: Executive compensation is detailed, with a focus on base salary and performance-based/time-based RSUs. The merger will bring significant changes to their roles and responsibilities.

Next Steps

• Stockholders will receive proxy materials for the 2026 Annual Meeting of Stockholders.
• Stockholders will vote on the election of directors, ratification of the independent auditor, and advisory approval of executive compensation at the Annual Meeting.
• Stockholders will vote on the merger agreement at a separate Special Meeting.
• The merger with Boston Scientific is expected to close by the end of 2026, subject to approvals.
• Final voting results from the Annual Meeting will be reported in a Form 8-K.

Key Dates

Recommendation

The filing primarily concerns the upcoming annual meeting and the proposed merger with Boston Scientific. While the merger offers a significant premium, the outcome is contingent on stockholder and regulatory approval. The routine nature of the annual meeting proposals and the disclosure of a director's past legal settlement warrant a 'hold' recommendation until the merger's completion or further developments.

Keywords

Penumbra Inc., Proxy Statement, Annual Meeting, Boston Scientific, Merger Agreement, Director Election, Independent Auditor, Executive Compensation, Corporate Governance, SEC Filing